CDTX Cidara Therapeutics, Inc.

Nasdaq cidara.com


$ 217.82 $ 0.41 (0.19 %)    

Friday, 14-Nov-2025 14:25:09 EST
QQQ $ 611.34 $ 11.78 (1.96 %)
DIA $ 473.18 $ 1.76 (0.37 %)
SPY $ 674.20 $ 8.75 (1.31 %)
TLT $ 88.96 $ -0.83 (-0.93 %)
GLD $ 376.61 $ 3.74 (1 %)
$ 105.99
$ 217.95
$ 217.82 x 144
$ 217.80 x 210
$ 216.80 - $ 218.84
$ 13.82 - $ 121.21
654,575
na
3.33B
$ 1.86
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 03-06-2025 01-01-1970 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-15-2024 03-31-2024 10-Q
8 04-22-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-23-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-11-2022 03-31-2022 10-Q
16 03-07-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-12-2021 06-30-2021 10-Q
19 05-13-2021 03-31-2021 10-Q
20 02-25-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-13-2020 06-30-2020 10-Q
23 05-13-2020 03-31-2020 10-Q
24 03-04-2020 12-31-2019 10-K
25 11-08-2019 09-30-2019 10-Q
26 08-08-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 02-28-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-09-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 02-27-2018 12-31-2017 10-K
33 11-08-2017 09-30-2017 10-Q
34 08-09-2017 06-30-2017 10-Q
35 05-10-2017 03-31-2017 10-Q
36 03-15-2017 12-31-2016 10-K
37 11-10-2016 09-30-2016 10-Q
38 08-11-2016 06-30-2016 10-Q
39 05-12-2016 03-31-2016 10-Q
40 03-18-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-downgrades-cidara-therapeutics-to-neutral

HC Wainwright & Co. analyst Sara Nik downgrades Cidara Therapeutics (NASDAQ:CDTX) from Buy to Neutral.

 needham-downgrades-cidara-therapeutics-to-hold

Needham analyst Joseph Stringer downgrades Cidara Therapeutics (NASDAQ:CDTX) from Buy to Hold.

 merck-makes-big-bet-on-flu-protection-with-cidara-buyout

Merck (NYSE: MRK) to acquire Cidara (NASDAQ: CDTX) for $9.2 billion, diversifying its portfolio with CD388.

Core News & Articles

https://www.ft.com/content/743e1962-3dd1-4785-a20b-4b097e5514ae

 why-is-cidara-therapeutics-cdtx-stock-trending-overnight

Cidara Therapeutics shares jumped over 42% in after-hours trading following a 13D filing and Phase 3 enrollment milestone.

 rbc-capital-maintains-outperform-on-cidara-therapeutics-raises-price-target-to-145

RBC Capital analyst Brian Abrahams maintains Cidara Therapeutics (NASDAQ:CDTX) with a Outperform and raises the price target...

 needham-maintains-buy-on-cidara-therapeutics-raises-price-target-to-135

Needham analyst Joseph Stringer maintains Cidara Therapeutics (NASDAQ:CDTX) with a Buy and raises the price target from $100...

 update-cidara-therapeutics-q3-adj-eps-143-misses-135-estimate

Cidara Therapeutics (NASDAQ:CDTX) reported quarterly losses of $(1.43) per share which missed the analyst consensus estimate of...

 cidara-therapeutics-presents-data-on--cd388-candidate-at-european-scientific-working-group-on-influenza-in-spain

Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION